Sinusitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Sinusitis Market Outlook

Thelansis’s “Sinusitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sinusitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sinusitis Overview

Sinusitis is inflammation of the sinuses, which are air-filled cavities in the skull. Causes are a combination of environmental and host factors. Acute sinusitis is most commonly due to viruses and is usually self-limiting. Around 90% of individuals with common colds also experience viral sinusitis to some degree. Those with atopy commonly get sinusitis. It can be caused by allergens, fungi, viruses, irritants, and bacteria. Popular irritants are animal dander, polluted air, smoke, and dust. Sinusitis can be categorized into the following groups:

1. Acute Rhinosinusitis: This condition is characterized by a sudden onset and typically lasts for less than 4 weeks, with symptoms resolving completely.
2. Subacute Rhinosinusitis: Subacute rhinosinusitis represents a continuation of acute rhinosinusitis, but it persists for a duration of less than 12 weeks.
3. Recurrent Acute Rhinosinusitis: This condition is defined by the occurrence of four or more episodes of acute rhinosinusitis, each lasting at least 7 days, within a single year.
4. Chronic Rhinosinusitis: Chronic rhinosinusitis is diagnosed when signs and symptoms persist for 12 weeks or longer.

Most commonly, a viral upper respiratory infection causes rhinosinusitis secondary to edema and inflammation of the nasal lining and the production of thick mucus that obstructs the paranasal sinuses and allows a secondary bacterial overgrowth. There are frontal, maxillary, sphenoid, and ethmoid sinuses. Allergic rhinitis can lead to sinusitis also due to ostial obstruction. Ciliary immobility can lead to increased mucus viscosity, further blocking drainage. Bacteria are introduced into the sinuses by coughing and nose blowing. Bacterial sinusitis usually occurs after a viral upper respiratory infection and worsening symptoms after 5 days or persistent symptoms after 10 days. The most common malady mistaken for sinusitis is rhinitis or an upper respiratory infection. A maxillary toothache can also mimic the pain caused by maxillary sinusitis. Tension headaches, vascular headaches, foreign bodies, brain abscesses, epidural abscesses, meningitis, and subdural empyema can also be mistaken for sinusitis. Most cases of uncomplicated acute bacterial sinusitis (ABS) can be treated on an outpatient basis with a good prognosis. Frontal or sphenoid sinusitis with air-fluid levels may require hospitalization with intravenous (IV) antibiotics. Patients who are immunocompromised or are toxic appearing require admission. Fungal sinusitis is associated with high morbidity and mortality. The recommended initial treatment for uncomplicated acute sinusitis has traditionally been a two-week course of antibiotics, with amoxicillin being one of the preferred choices. The selected antibiotic should effectively target bacteria such as Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. This coverage is crucial because rare but intracranial severe and orbital complications of acute bacterial sinusitis are often associated with S. pneumoniae, particularly in individuals with compromised immune systems. Another suitable option for treating uncomplicated acute sinusitis is amoxicillin-clavulanate, which includes clavulanate, a beta-lactamase inhibitor that enhances coverage against H. influenzae and M. catarrhalis. Additional antibiotic choices for treating this condition include cephalosporins like cefpodoxime proxetil and cefuroxime. Patients with allergies to beta-lactam antibiotics can consider alternatives such as trimethoprim-sulfamethoxazole, clarithromycin, and azithromycin.

• Sinusitis impacts approximately one in seven adults in the United States, which amounts to over 30 million individuals each year. This condition is more prevalent among adults compared to children.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: